Pancreatic Cancer Study Reaches 10,000 Participants Worldwide
The PRECEDE Consortium doubles its enrollment target to 20,000 as it builds a dataset for early detection tool development.
The PRECEDE Consortium doubles its enrollment target to 20,000 as it builds a dataset for early detection tool development.
PharusDx announced a liquid biopsy test that uses microRNA and CA19-9 biomarkers to detect early-stage pancreatic cancer.
Immunovia has been selected for a US-government-funded study to evaluate biomarker tests for monitoring pancreatic cystic neoplasms.
An artificial intelligence tool has successfully identified those at the highest risk for pancreatic cancer up to 3 years before diagnosis.
Read MoreSinglera Genomics’ PDACatch assay is a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.
Read MoreA research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.
Read MoreBluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.
Read MoreNew research points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.
Read MoreBluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test. Â
Read MorePancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.
Read MoreThe CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.Â
Read MoreThe PancreaSeq molecular test accurately classifies pancreatic cysts as potentially cancerous or benign, a large, multi-center study found.
Read MorePersonalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.
Read MorePancreatic ductal adenocarcinoma affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate under 10%.
Read MoreResearchers have found a molecular signature in stool samples that could predict whether patients are at high risk of pancreatic cancer.
Read MoreYale Cancer Center early detection research is providing new reason for optimism for the diagnosis of pancreatic cancer.
Read MoreBluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.
Read MoreNew research showed that blood tests may be the future of pancreatic cancer detection. Pancreatic cancer is one of the most deadly forms of the disease.
Read More